Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
04 2019
Historique:
received: 10 08 2018
revised: 30 10 2018
accepted: 12 12 2018
pubmed: 16 1 2019
medline: 4 6 2020
entrez: 16 1 2019
Statut: ppublish

Résumé

Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with respect to onset, progression, and response to therapy. Incorporating clinical- and imaging-based features to refine COPD phenotypes provides valuable information beyond that obtained from traditional clinical evaluations. We characterized the spectrum of COPD-related phenotypes in a sample of former and current smokers and evaluated how these subgroups differ with respect to sociodemographic characteristics, COPD-related comorbidities, and subsequent risk of lung cancer. White ( Five clusters were identified that differed significantly with respect to sociodemographic (e.g., race, age) and clinical (e.g., BMI, limitations due to breathing difficulties) characteristics. Increased risk of lung cancer was associated with increasingly detrimental lung function clusters (when ordered from most detrimental to least detrimental). Measures of lung function vary considerably among smokers and are not fully explained by smoking intensity. Combining clinical (spirometry) and radiologic (qCT) measures of COPD defines a spectrum of lung disease that predicts lung cancer risk differentially among patient clusters.

Sections du résumé

BACKGROUND
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition with respect to onset, progression, and response to therapy. Incorporating clinical- and imaging-based features to refine COPD phenotypes provides valuable information beyond that obtained from traditional clinical evaluations. We characterized the spectrum of COPD-related phenotypes in a sample of former and current smokers and evaluated how these subgroups differ with respect to sociodemographic characteristics, COPD-related comorbidities, and subsequent risk of lung cancer.
METHODS
White (
RESULTS
Five clusters were identified that differed significantly with respect to sociodemographic (e.g., race, age) and clinical (e.g., BMI, limitations due to breathing difficulties) characteristics. Increased risk of lung cancer was associated with increasingly detrimental lung function clusters (when ordered from most detrimental to least detrimental).
CONCLUSIONS
Measures of lung function vary considerably among smokers and are not fully explained by smoking intensity.
IMPACT
Combining clinical (spirometry) and radiologic (qCT) measures of COPD defines a spectrum of lung disease that predicts lung cancer risk differentially among patient clusters.

Identifiants

pubmed: 30642838
pii: 1055-9965.EPI-18-0886
doi: 10.1158/1055-9965.EPI-18-0886
pmc: PMC6449213
mid: NIHMS1517121
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

724-730

Subventions

Organisme : NCI NIH HHS
ID : P30 CA086862
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA141769
Pays : United States
Organisme : CCR NIH HHS
ID : HHSN261201300011C
Pays : United States
Organisme : NCI NIH HHS
ID : N01 PC065064
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA022453
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201300011I
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL112986
Pays : United States
Organisme : NIEHS NIH HHS
ID : P30 ES005605
Pays : United States

Informations de copyright

©2019 American Association for Cancer Research.

Références

Eur J Radiol. 2016 Nov;85(11):2144-2151
pubmed: 27776670
Chest. 2009 Aug;136(2):396-404
pubmed: 19411295
Eur Respir J. 2005 Nov;26(5):948-68
pubmed: 16264058
Clin Chest Med. 2014 Mar;35(1):1-6
pubmed: 24507832
Ann Am Thorac Soc. 2015 Mar;12(3):303-12
pubmed: 25642832
J Thorac Imaging. 2009 Aug;24(3):189-94
pubmed: 19704322
Am J Respir Crit Care Med. 1999 Jan;159(1):179-87
pubmed: 9872837
Thorax. 2014 May;69(5):415-22
pubmed: 24563194
Am J Respir Crit Care Med. 2006 Jun 15;173(12):1326-34
pubmed: 16543549
Am J Respir Crit Care Med. 2016 Oct 1;194(7):794-806
pubmed: 27482984
Eur J Radiol. 2017 Jan;86:335-342
pubmed: 27592252
Radiology. 2008 Sep;248(3):1042-9
pubmed: 18710993
PLoS One. 2012;7(12):e51048
pubmed: 23236428
Eur Respir J. 1999 Feb;13(2):252-6
pubmed: 10065664
Eur Radiol. 2012 Oct;22(10):2085-93
pubmed: 22699870
AJR Am J Roentgenol. 2013 Sep;201(3):W460-70
pubmed: 23971478
Am J Respir Crit Care Med. 2013 Feb 15;187(4):347-65
pubmed: 22878278
Eur Respir J. 2009 Oct;34(4):812-8
pubmed: 19357143
Chest. 2006 Jul;130(1):108-18
pubmed: 16840390
Respir Res. 2010 Mar 16;11:30
pubmed: 20233420
Cancer Epidemiol Biomarkers Prev. 2016 Sep;25(9):1341-7
pubmed: 27383774
Respir Res. 2010 Sep 10;11:122
pubmed: 20831787
Eur Respir J. 2013 Sep;42(3):636-46
pubmed: 23766334

Auteurs

Christine M Lusk (CM)

Karmanos Cancer Institute, Detroit, Michigan.
Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan.

Angela S Wenzlaff (AS)

Karmanos Cancer Institute, Detroit, Michigan.
Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan.

Donovan Watza (D)

Karmanos Cancer Institute, Detroit, Michigan.
Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan.

Jessica C Sieren (JC)

Department of Radiology, Carver College of Medicine, University of Iowa, Iowa City, Iowa.

Natasha Robinette (N)

Department of Radiology, Karmanos Cancer Institute, Detroit, Michigan.

Garrett Walworth (G)

Department of Radiology, Karmanos Cancer Institute, Detroit, Michigan.

Michael Petrich (M)

Department of Radiology, Karmanos Cancer Institute, Detroit, Michigan.

Christine Neslund-Dudas (C)

Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan.
Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.

Michael J Flynn (MJ)

Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan.
Department of Radiology, Henry Ford Health System, Detroit, Michigan.

Thomas Song (T)

Department of Radiology, Henry Ford Health System, Detroit, Michigan.

David Spizarny (D)

Department of Public Health Sciences, Henry Ford Health System, Detroit, Michigan.
Department of Radiology, Henry Ford Health System, Detroit, Michigan.

Michael J Simoff (MJ)

Josephine Ford Cancer Institute, Henry Ford Health System, Detroit, Michigan.
Division of Pulmonary and Critical Care Medicine, Henry Ford Health System, Detroit, Michigan.

Ayman O Soubani (AO)

Karmanos Cancer Institute, Detroit, Michigan.
Department of Internal Medicine, School of Medicine, Wayne State University, Detroit, Michigan.

Shirish Gadgeel (S)

Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.

Ann G Schwartz (AG)

Karmanos Cancer Institute, Detroit, Michigan. schwarta@karmanos.org.
Department of Oncology, School of Medicine, Wayne State University, Detroit, Michigan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH